Large-scale production and purification of VLP-based vaccines

Tiago Vicente; António Roldão; Cristina Peixoto; Manuel José Teixeira Carrondo; Paula Maria Alves

doi:10.1016/j.jip.2011.05.004

Large-scale production and purification of VLP-based vaccines

Tiago Vicente, António Roldão, Cristina Peixoto, Manuel José Teixeira Carrondo, Paula Maria Alves

Research output: Contribution to journal › Article › peer-review

227 Citations (Scopus)

Abstract

Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These innovative biopharmaceuticals present the remarkable advantages of closely mimicking the three-dimensional nature of an actual virus while lacking the virus genome packaged inside its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to inactivated or live attenuated viral vaccines. With the advent of successful cases of approved VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to the development of such products. This paper reviews the current choices and trends of large-scale production and purification of VLP-based vaccines generated through the baculovirus expression vector system using insect cells. (C) 2011 Elsevier Inc. All rights reserved.

Original language	English
Pages (from-to)	S42S48
Journal	Journal Of Invertebrate Pathology
Volume	107
Issue number	NA
DOIs	https://doi.org/10.1016/j.jip.2011.05.004
Publication status	Published - 1 Jul 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jip.2011.05.004

Cite this

@article{adcf617863234f409cfc68f277db0057,

title = "Large-scale production and purification of VLP-based vaccines",

abstract = "Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These innovative biopharmaceuticals present the remarkable advantages of closely mimicking the three-dimensional nature of an actual virus while lacking the virus genome packaged inside its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to inactivated or live attenuated viral vaccines. With the advent of successful cases of approved VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to the development of such products. This paper reviews the current choices and trends of large-scale production and purification of VLP-based vaccines generated through the baculovirus expression vector system using insect cells. (C) 2011 Elsevier Inc. All rights reserved.",

keywords = "EXPRESSION SYSTEM, ROTAVIRUS-LIKE PARTICLES, IMMUNE-RESPONSES, EXCHANGE MEMBRANE CHROMATOGRAPHY, QUANTITATIVE-ANALYSIS, RECOMBINANT BACULOVIRUSES, INSECT CELLS, CULTURE SUPERNATANT, VIRUS-LIKE PARTICLES, PROTEIN-PRODUCTION",

author = "Tiago Vicente and Ant{\'o}nio Rold{\~a}o and Cristina Peixoto and Carrondo, {Manuel Jos{\'e} Teixeira} and Alves, {Paula Maria}",

note = "Tiago Vicente Ant{\'o}nio Rold{\~a}o",

year = "2011",

month = jul,

day = "1",

doi = "10.1016/j.jip.2011.05.004",

language = "English",

volume = "107",

pages = "S42S48",

journal = "Journal Of Invertebrate Pathology",

issn = "0022-2011",

publisher = "Elsevier Science B.V., Amsterdam.",

number = "NA",

}

TY - JOUR

T1 - Large-scale production and purification of VLP-based vaccines

AU - Vicente, Tiago

AU - Roldão, António

AU - Peixoto, Cristina

AU - Carrondo, Manuel José Teixeira

AU - Alves, Paula Maria

N1 - Tiago Vicente António Roldão

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These innovative biopharmaceuticals present the remarkable advantages of closely mimicking the three-dimensional nature of an actual virus while lacking the virus genome packaged inside its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to inactivated or live attenuated viral vaccines. With the advent of successful cases of approved VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to the development of such products. This paper reviews the current choices and trends of large-scale production and purification of VLP-based vaccines generated through the baculovirus expression vector system using insect cells. (C) 2011 Elsevier Inc. All rights reserved.

AB - Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These innovative biopharmaceuticals present the remarkable advantages of closely mimicking the three-dimensional nature of an actual virus while lacking the virus genome packaged inside its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to inactivated or live attenuated viral vaccines. With the advent of successful cases of approved VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to the development of such products. This paper reviews the current choices and trends of large-scale production and purification of VLP-based vaccines generated through the baculovirus expression vector system using insect cells. (C) 2011 Elsevier Inc. All rights reserved.

KW - EXPRESSION SYSTEM

KW - ROTAVIRUS-LIKE PARTICLES

KW - IMMUNE-RESPONSES

KW - EXCHANGE MEMBRANE CHROMATOGRAPHY

KW - QUANTITATIVE-ANALYSIS

KW - RECOMBINANT BACULOVIRUSES

KW - INSECT CELLS

KW - CULTURE SUPERNATANT

KW - VIRUS-LIKE PARTICLES

KW - PROTEIN-PRODUCTION

U2 - 10.1016/j.jip.2011.05.004

DO - 10.1016/j.jip.2011.05.004

M3 - Article

C2 - 21784230

SN - 0022-2011

VL - 107

SP - S42S48

JO - Journal Of Invertebrate Pathology

JF - Journal Of Invertebrate Pathology

IS - NA

ER -

Large-scale production and purification of VLP-based vaccines

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this